Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Notices to Readers Availability of Primaquine Phosphate from CDC

Primaquine phosphate is an antimalarial drug that decreases the risk of malaria relapses by acting against the liver stages of Plasmodium vivax and P. ovale infections. No alternative antirelapse drugs are available in the United States.

CDC was recently notified by the sole U.S. manufacturer of primaquine (Winthrop Pharmaceuticals, New York, New York) that production of this drug has been temporarily discontinued because its chemical precursor is currently unavailable. Primaquine is expected to be commercially available again in mid-1991. In the meantime, CDC has acquired a supply of the drug in sufficient quantity for treatment of nonmilitary cases of P. vivax and P. ovale infections. Until primaquine is again commercially available, CDC will provide this drug free to licensed U.S. physicians who wish to prescribe it for patients who have parasitologically-confirmed P. vivax or P. ovale infections and who reside in the United States or its territories. Patients with P. falciparum or P. malariae infections do not require primaquine therapy. Because of the limited supply, CDC is unable to provide primaquine for persons who wish to use it as part of a chemoprophylactic regimen.

Physicians who wish to receive therapeutic courses of primaquine for their patients should call the CDC Drug Service at (404) 639-3670, Monday through Friday, between 8:00 a.m. and 4:30 p.m. Eastern time. Physicians will be requested to provide the following information about their patients: clinical and parasitologic data, places and dates of travel to malarious areas, and use of malaria chemoprophylaxis.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version ( and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #